New therapeutic targets in the management of advanced gastric cancer
Academia Oncology · 2024
DOI: 10.20935/acadonco7447 ↗Kurz gefasst
Fachartikel in der Zeitschrift Academia Oncology, 2024. Verfasst von Paula Gomila Pons und 2 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
The treatment of advanced gastric cancer remains challenging due to its late diagnosis and aggressive nature. HER2 inhibitors like trastuzumab deruxtecan (T-DXd) show significant efficacy in HER2-positive gastric cancer. Drugs targeting claudin 18.2 such as zolbetuximab and drugs targeting fibroblast growth factor 2b such as bemarituzumab have shown promising results in clinical trials. Immune checkpoint inhibitors such as pembrolizumab and nivolumab exhibit striking efficacy in select patient cohorts, particularly those exhibiting microsatellite instability. This review highlights the transformative potential of emerging therapeutic targets in the fight against advanced gastric cancer, emphasizing the need for ongoing innovation and clinical research.
Zitieren
APA
Pons, P. G., Abad, C. B., & Pazo-Cid, R. (2024). New therapeutic targets in the management of advanced gastric cancer. Academia Oncology. https://doi.org/10.20935/acadonco7447
Vancouver
Pons PG, Abad CB, Pazo-Cid R. New therapeutic targets in the management of advanced gastric cancer. Academia Oncology. 2024. doi:10.20935/acadonco7447
BibTeX
@article{Pons2024,
author = {Pons, Paula Gomila and Abad, Carmen Blanco and Pazo-Cid, Roberto},
title = {New therapeutic targets in the management of advanced gastric cancer},
journal = {Academia Oncology},
year = {2024},
doi = {10.20935/acadonco7447}
}
EUVIMED